Pharmaceutical Executive
The last thing on the mind of an adventurous traveler is a pre-trip immunization, which, consequently, is not top-of-mind for their healthcare providers, either.
POSTCARDS
ICC
BRAND TravelWise Program CLIENT Sanofi Pasteur AT RIGHT: Chet Moss, executive vice president, chief creative officer NOT PICTURED: Karen Neale, writer; Suzanne Elward, art director
The last thing on the mind of an adventurous traveler is a pre-trip immunization, which, consequently, is not top-of-mind for their healthcare providers, either. The work of ICC for Sanofi Pasteur helped deepen the necessary dialogue and increase awareness of the need for vaccination when traveling to many far-off lands through the use of classic souvenir postcards from more than 50 years ago.
The campaign embraced multiple tactics all predicated on the visual parody of the postcards. "The marketing challenge was to get people to pay attention to these insidious diseases lurking in foreign lands, and to ramp up the discussion between healthcare provider and traveler," notes Chet Moss, executive vice president, chief creative officer of ICC. "It was done in a warm and approachable way."
Each card was driven by the same call to action: "Be Aware...Prepare!" Yet each advertisement features a surprising twist. For instance, expecting to see Yellowstone National Park on the postcard, the airbrushed message reveals another possible destination: Yellow Fever. "You can't help but pay attention," says Moss. "You take common ground and put a twist on it...and that's what great advertising is about."
What Every Pharma CEO Should Know About Unlocking the Potential of Scientific Data
December 11th 2024When integrated into pharmaceutical enterprises, scientific data has the potential to drive organizational growth and innovation. Mikael Hagstroem, CEO at leading laboratory informatics provider LabVantage Solutions, discusses how technology partners add significant value to pharmaceutical R&D, in addition to manufacturing quality.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.